Clinical trials: Pancreatic Cancer Stage I
Pancreatic Cancer
Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00536874
- Testing
- gemcitabine hydrochloride, oxaliplatin, protein expression analysis
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Cancer
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient's specific tumour type.
- Trial name
- MODULATE (NCT03009058)
- Testing
- IMM-101, Gemcitabine, Nab-paclitaxel
- Where
- 4 sites in France, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Immodulon Therapeutics Ltd
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
This study was conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03525392
- Testing
- 177Lu-3BP-227 (also called 177Lu-IPN01087)
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 14 people
- Sponsor
- Ipsen
Cancer, Solid Tumor
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Rationale: CALAA-01 is a targeted therapeutic designed to inhibit tumor growth and/or reduce tumor size. The active ingredient in CALAA-01 is a small interfering RNA (siRNA).
- Trial name
- NCT00689065
- Testing
- CALAA-01
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Calando Pharmaceuticals
Colorectal Cancer, Pancreatic Cancer
Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. QS21 may improve the ability of the immune system to respond to disease. Combining vaccine therapy with QS21 may kill more tumor cells.
- Trial name
- NCT00006387
- Testing
- QS21, ras peptide cancer vaccine
- Volunteers
- 7 people
- Sponsor
- Fox Chase Cancer Center
Pancreatic Cancer
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
The purpose of this study is to see if LOAd703 (an oncolytic adenovirus) can be safely given to patients with pancreatic cancer.
- Trial name
- NCT02705196
- Testing
- delolimogene mupadenorepvec, gemcitabine, nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Lokon Pharma AB
Advance Solid Tumors, Colon and Rectal Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
- Conditions
- Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic
- Trial name
- NCT07610798
- Testing
- INV-8989
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Solid Tumor, Non-Small Cell Lung Cancer
GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results
Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors. Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT05183243
- Testing
- GH21 Capsule
- Where
- 9 sites in China
- Volunteers
- 68 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
Glioblastoma Multiforme, Brain Neoplasms
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
This is a First-In-Human (FIH) study of [68Ga]-FF58 to characterize the imaging properties, safety, biodistribution and dosimetry properties of [68Ga]-FF58 in adults with relapsed or refractory (r/r) glioblastoma multiforme…
- Conditions
- Glioblastoma Multiforme, Brain Neoplasms, Gastroesophageal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT04712721
- Testing
- 68Ga-FF58
- Where
- 2 sites in France, Germany
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
PURPOSE: This phase II trial is studying how well gemcitabine and erlotinib work when given before and after surgery in treating patients with pancreatic cancer that can be removed by surgery.
- Trial name
- NCT00733746
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, therapeutic conventional surgery
- Where
- 24 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer
Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
Phase I trail will be conducted to evaluate the safety of M2ES in combination with gemcitabine in locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT01218880
- Testing
- M2ES 7.5mg, M2ES 15mg, M2ES 30mg
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Beijing Protgen Biotechnology Development Co., Ltd.
Breast Cancer, Colorectal Cancer
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- NCT00709462
- Testing
- CDX1307
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Celldex Therapeutics
Ovarian Cancer, Pancreatic Cancer
VM110 in Detection of Microscopic Tumors: A Phase I Study
A laproscopic imaging tecgnology that uses a synthetic agent to detect ovarian and pancreatic cancers at an early stage so that patients can get treatment early and prevent the disease from advancing to late stage leading to…
- Trial name
- NCT03286062
- Testing
- Agent VM110 and laproscopic infra-red probe
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Fox Chase Cancer Center
Pancreatic Cancer
Studying Biomarkers in Patients With Pancreatic Cancer
RATIONALE: Studying samples of tissue in the laboratory from patients with cancer may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900003
- Testing
- protein analysis, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Pancreatic Cancer
Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00010062
- Testing
- fluorouracil, radiation therapy
- Where
- 30 sites in France, Luxembourg
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
This study is a single-arm, phase I trial, up to 16 participants with resectable PDA. The study will examine the efficacy of the mutant IDH1 inhibitor ivosidenib, in conjunction with standard-of-care mFOLFIRINOX in the…
- Trial name
- NCT05209074
- Testing
- Ivosidenib, mFOLFIRINOX
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Case Comprehensive Cancer Center
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
ABC294640 in Treating Patients With Advanced Solid Tumors
This phase I trial studies the side effects and best dose of ABC294640 in treating patients with advanced solid tumors. ABC294640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- ABC-101 (NCT01488513)
- Testing
- sphingosine kinase-2 inhibitor ABC294640
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- RedHill Biopharma Limited
Pancreatic Neoplasms
Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic Cancer
The current standard treatment for patients with primarily resectable pancreatic tumors consists of surgery followed by adjuvant chemotherapy.
- Trial name
- NEOPANC (NCT01372735)
- Testing
- neoadjuvant short course IMRT, IORT
- Where
- 3 sites in Germany
- Volunteers
- 46 people
- Sponsor
- University Hospital Heidelberg
Cancer
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005860
- Testing
- floxuridine, leucovorin calcium, oxaliplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
Pancreatic cancer, most commonly adenocarcinoma, is the fourth leading cause of cancer death in the United States. The mainstay of management centers on surgical resection (if resectable) and although low (15% to 20%)…
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT03073785
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska